The bait-and-switch here is breathtaking. Still waiting to see shareholder value in terms of PPS (currently around .00018 adjusted for R/S) from the last 3 years: CaverStem “contract with Russia,” cachexia amelioration, universal donor cells associated with Amniostem, all the great marketing that was supposed to come from hiring Gary Mells. That’s all I’ve got off the top of my head—but it’s a plenty good start....